Cargando…
Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo
Microvesicles shed from cells carry constituents of the cell cytoplasm, including, of importance in multidrug resistance to cancer chemotherapy, drugs that the tumor cell attempts to efflux. To see whether such drugs could be used at lower concentrations with the same efficacy, it was first shown th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548233/ https://www.ncbi.nlm.nih.gov/pubmed/26302712 http://dx.doi.org/10.1038/srep13006 |
_version_ | 1782387174397706240 |
---|---|
author | Jorfi, Samireh Ansa-Addo, Ephraim A. Kholia, Sharad Stratton, Dan Valley, Shaunelle Lange, Sigrun Inal, Jameel |
author_facet | Jorfi, Samireh Ansa-Addo, Ephraim A. Kholia, Sharad Stratton, Dan Valley, Shaunelle Lange, Sigrun Inal, Jameel |
author_sort | Jorfi, Samireh |
collection | PubMed |
description | Microvesicles shed from cells carry constituents of the cell cytoplasm, including, of importance in multidrug resistance to cancer chemotherapy, drugs that the tumor cell attempts to efflux. To see whether such drugs could be used at lower concentrations with the same efficacy, it was first shown that microvesiculation of prostate cancer (PCa) cells, PC3, could be inhibited pharmacologically with calpeptin (calpain inhibitor) and by siRNA (CAPNS1). In cells treated with docetaxel (DTX), this inhibition resulted in a third-fold increase in intracellular concentrations of DTX. As a result, 20-fold lower concentrations of DTX (5 nM) could be used, in the presence of calpeptin (20 μM) inducing the same degree of apoptosis after 48 h in PC3 cells, as 100 nM of DTX alone. Inhibition of microvesiculation similarly improved combination chemotherapy (DTX and methotrexate). In a mouse xenograft model of PCa, DTX (0.1 mg/kg) together with calpeptin (10 mg/kg), administered i.p., significantly reduced tumor volumes compared to DTX alone (0.1 mg/kg) and brought about the same reductions in tumor growth as 10 mg/kg of DTX alone. As well as further reducing vascularization, it also increased apoptosis and reduced proliferation of PC3 cells in tumor xenografts. |
format | Online Article Text |
id | pubmed-4548233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45482332015-08-26 Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo Jorfi, Samireh Ansa-Addo, Ephraim A. Kholia, Sharad Stratton, Dan Valley, Shaunelle Lange, Sigrun Inal, Jameel Sci Rep Article Microvesicles shed from cells carry constituents of the cell cytoplasm, including, of importance in multidrug resistance to cancer chemotherapy, drugs that the tumor cell attempts to efflux. To see whether such drugs could be used at lower concentrations with the same efficacy, it was first shown that microvesiculation of prostate cancer (PCa) cells, PC3, could be inhibited pharmacologically with calpeptin (calpain inhibitor) and by siRNA (CAPNS1). In cells treated with docetaxel (DTX), this inhibition resulted in a third-fold increase in intracellular concentrations of DTX. As a result, 20-fold lower concentrations of DTX (5 nM) could be used, in the presence of calpeptin (20 μM) inducing the same degree of apoptosis after 48 h in PC3 cells, as 100 nM of DTX alone. Inhibition of microvesiculation similarly improved combination chemotherapy (DTX and methotrexate). In a mouse xenograft model of PCa, DTX (0.1 mg/kg) together with calpeptin (10 mg/kg), administered i.p., significantly reduced tumor volumes compared to DTX alone (0.1 mg/kg) and brought about the same reductions in tumor growth as 10 mg/kg of DTX alone. As well as further reducing vascularization, it also increased apoptosis and reduced proliferation of PC3 cells in tumor xenografts. Nature Publishing Group 2015-08-25 /pmc/articles/PMC4548233/ /pubmed/26302712 http://dx.doi.org/10.1038/srep13006 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Jorfi, Samireh Ansa-Addo, Ephraim A. Kholia, Sharad Stratton, Dan Valley, Shaunelle Lange, Sigrun Inal, Jameel Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title_full | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title_fullStr | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title_full_unstemmed | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title_short | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
title_sort | inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548233/ https://www.ncbi.nlm.nih.gov/pubmed/26302712 http://dx.doi.org/10.1038/srep13006 |
work_keys_str_mv | AT jorfisamireh inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT ansaaddoephraima inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT kholiasharad inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT strattondan inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT valleyshaunelle inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT langesigrun inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo AT inaljameel inhibitionofmicrovesiculationsensitizesprostatecancercellstochemotherapyandreducesdocetaxeldoserequiredtolimittumorgrowthinvivo |